Theranostics · 2024 · 10 citations · 41 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyMolecular OncologyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune Checkpoint RegulationImmune RegulationImmuno-oncology BiomarkersPd-l1 BlockadePredictive BiomarkersProgrammed Cell Death Protein 1 (Pd-1) PathwayProgrammed Death 1 SignalingProgrammed Death-ligand 1 BiomarkerSphingosine 1-Phosphate SignalingSphingosine-1-phosphate SignalingTherapeutic Response Prediction
Our study reveals a novel role for SPHK1 in mediating immune evasion in HNSCC through the regulation of the MMP1-PD-L1 axis. We identified SPHK1 and MMP1 as predictive biomarkers for the therapeutic response to PD-1 mAb and provided new therapeutic targets for patients with HNSCC.
41
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
Se Jin Im, Masao Hashimoto, Michael Y. Gerner et al. · Nature · 2016 · 2.1K citations · Full text
Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade
Joy Hsu, Jonathan J. Hodgins, Malvika Marathe et al. · Journal of Clinical Investigation · 2018 · 827 citations · Full text
Life Sciences, Immunology, Oncology +17
Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas
A.J. Schoenfeld, H. Rizvi, Chai Bandlamudi et al. · Annals of Oncology · 2020 · 341 citations · Full text